https://www.selleckchem.com/products/ru-521.html
037). TAVR was associated with a significantly lower risk of AKI [RR = 0.72 (95% CI 0.62-0.83), p less then 0.001] and a lower risk of transfusion [RR = 0.71 (95% CI 0.62-0.81), p less then 0.001]. There was no difference in risk of stroke/TIA[RR = 1.01 (95% CI 0.70-1.45), p = 0.957]. The risk of vascular complications was significantly higher in the TAVR group [RR = 3.39 (95% CI 2.65-4.333), p less then 0.001]. Conclusion In this high-risk population, TAVR compared to SAVR has similar short-term mortality benefit but has lower risks of
Like
Comment
Share
